Weipeng Gong1,2, Lei Zhao1, Zhaogang Dong3, Yu Dou1, Yanguo Liu4, Chao Ma1, Xun Qu1. 1. Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan, Shandong, China. 2. Department of Surgical Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China. 3. Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, China. 4. Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Abstract
INTRODUCTION: Circulating predictors prognostic factors of neoadjuvant chemotherapy, which identify the patients who are potential possibly to benefit from it are limited at present. In this research, we aimed to compare the prognostic significance of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patients with locally advance gastric carcinoma who were treated with neoadjuvant chemotherapy (NAC) followed by D2 gastrectomy. MATERIALS AND METHODS: From 2007 to 2015, 91 patients with locally advanced gastric cancer treated with NAC followed by D2 gastrectomy included in this retrospective cohort study. The correlation of clinical data, including tumor regression, response evaluation, tumor location, pathological type, systemic therapy, tumor size (cm), neural invasion, lymphatic-vascular invasion, ypTNM stage, and survival prognosis were analyzed. RESULTS: Platelet/lymphocyte ratio and neutrophil/lymphocyte ratio in gastric cancer patients were higher than in matched normal volunteers. PLR levels higher after neoadjuvant chemotherapy are associated with worse OS. Multivariate Cox proportional analysis showed that pre-neoadjuvant chemotherapy PLR was an independent prognostic factor. CONCLUSIONS: Pre-neoadjuvant chemotherapy PLR may be a feasible biomarker for survival prognosis in patients with locally advanced gastric cancer. PLR and NLR were reduced after neoadjuvant chemotherapy. After neoadjuvant chemotherapy, PLR level was negatively correlated with survival prognosis.
INTRODUCTION: Circulating predictors prognostic factors of neoadjuvant chemotherapy, which identify the patients who are potential possibly to benefit from it are limited at present. In this research, we aimed to compare the prognostic significance of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patients with locally advance gastric carcinoma who were treated with neoadjuvant chemotherapy (NAC) followed by D2 gastrectomy. MATERIALS AND METHODS: From 2007 to 2015, 91 patients with locally advanced gastric cancer treated with NAC followed by D2 gastrectomy included in this retrospective cohort study. The correlation of clinical data, including tumor regression, response evaluation, tumor location, pathological type, systemic therapy, tumor size (cm), neural invasion, lymphatic-vascular invasion, ypTNM stage, and survival prognosis were analyzed. RESULTS: Platelet/lymphocyte ratio and neutrophil/lymphocyte ratio in gastric cancerpatients were higher than in matched normal volunteers. PLR levels higher after neoadjuvant chemotherapy are associated with worse OS. Multivariate Cox proportional analysis showed that pre-neoadjuvant chemotherapy PLR was an independent prognostic factor. CONCLUSIONS: Pre-neoadjuvant chemotherapy PLR may be a feasible biomarker for survival prognosis in patients with locally advanced gastric cancer. PLR and NLR were reduced after neoadjuvant chemotherapy. After neoadjuvant chemotherapy, PLR level was negatively correlated with survival prognosis.
Authors: Yoji Kishi; Scott Kopetz; Yun Shin Chun; Martin Palavecino; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: Ann Surg Oncol Date: 2009-01-08 Impact factor: 5.344
Authors: Christoph Schuhmacher; Stephan Gretschel; Florian Lordick; Peter Reichardt; Werner Hohenberger; Claus F Eisenberger; Cornelie Haag; Murielle E Mauer; Baktiar Hasan; John Welch; Katja Ott; Arnulf Hoelscher; Paul M Schneider; Wolf Bechstein; Hans Wilke; Manfred P Lutz; Bernard Nordlinger; Eric Van Cutsem; Jörg R Siewert; Peter M Schlag Journal: J Clin Oncol Date: 2010-11-08 Impact factor: 44.544
Authors: Alexander Stahl; Katja Ott; Wolfgang Andreas Weber; Karen Becker; Thomas Link; Jörg-Rüdiger Siewert; Markus Schwaiger; Ulrich Fink Journal: Eur J Nucl Med Mol Imaging Date: 2002-11-08 Impact factor: 9.236
Authors: Sabine Schiefer; Naita Maren Wirsik; Eva Kalkum; Svenja Elisabeth Seide; Henrik Nienhüser; Beat Müller; Adrian Billeter; Markus W Büchler; Thomas Schmidt; Pascal Probst Journal: Diagnostics (Basel) Date: 2022-02-25